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Abstract
Objectives To examine the costs of caring for community-dwelling patients with Alzheimer’s disease (AD) dementia in 
relation to the time to institutionalisation.
Methods GERAS was a prospective, non-interventional cohort study in community-dwelling patients with AD dementia 
and their caregivers in three European countries. Using identified factors associated with time to institutionalisation, models 
were developed to estimate the time to institutionalisation for all patients. Estimates of monthly total societal costs, patient 
healthcare costs and total patient costs (healthcare and social care together) prior to institutionalisation were developed as a 
function of the time to institutionalisation.
Results Of the 1495 patients assessed at baseline, 307 (20.5%) were institutionalised over 36 months. Disease severity at 
baseline [based on Mini-Mental State Examination (MMSE) scores] was associated with risk of being institutionalised during 
follow up (p < 0.001). Having a non-spousal informal caregiver was associated with a faster time to institutionalisation (944 
fewer days versus having a spousal caregiver), as was each one-point worsening in baseline score of MMSE, instrumental 
activities of daily living and behavioural disturbance (67, 50 and 30 fewer days, respectively). Total societal costs, total 
patient costs and, to a lesser extent, patient healthcare-only costs were associated with time to institutionalisation. In the 5 
years pre-institutionalisation, monthly total societal costs increased by more than £1000 (€1166 equivalent for 2010) from 
£1900 to £3160 and monthly total patient costs almost doubled from £770 to £1529.
Conclusions Total societal costs and total patient costs rise steeply as community-dwelling patients with AD dementia 
approach institutionalisation.
Keywords Alzheimer’s disease · Societal costs · Institutionalisation · Predictors · Caregiver
JEL Classification I00 (Health Education and Welfare: General) · I10 (Health: General) · I19 (Health: Other)
Introduction
Cost-of-illness (COI) studies have shown that the two most 
important cost drivers in dementia care from a societal per-
spective are the costs of institutional care and the costs of 
informal care for patients who are cared for at home [1, 2].
Time to institutionalisation (also referred to as ‘nursing 
home placement’ or ‘transition into a care home’) is often 
used as an outcome measure in Alzheimer’s disease (AD) 
dementia trials. The median time to institutionalisation in 
dementia studies has been estimated to be between 30 and 
40 months from study entry, but this depends on the severity 
of the patient’s disease at the time of study entry [3]. One 
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of the goals of AD dementia management (including drug 
treatment) is to improve treatment in the community setting 
and stabilise the course of the disease, which may prolong 
the time to institutionalisation of people with dementia [4, 
5]. This is especially true in high-income countries, where 
long-term institutional care constitutes a substantial part of 
care for people with dementia [6]. Delaying institutionalisa-
tion may increase the time patients with AD dementia can 
spend with their family and friends, improve quality of life 
and increase life expectancy [7]. It may also potentially be 
cost-saving from a societal perspective [5], although this is 
not fully supported by current evidence [8, 9].
Economic models of AD assessing long-term costs and 
outcomes generally use modelling techniques to extrapolate 
from short-term data because the follow-up periods in clini-
cal trials are usually too short to measure parameters such 
as institutionalisation and death. To better estimate these 
models, detailed knowledge of the factors associated with 
patient care and societal costs is necessary. Time to institu-
tionalisation could potentially be a significant determinant 
of societal costs in patients with AD dementia. However, it 
has only been used in a few model-based economic evalu-
ations in AD dementia [10, 11]. There is a need for more 
data on the costs incurred during the pre-institutionalisation 
phase from a societal perspective to determine whether costs 
increase substantially for patients approaching institutionali-
sation. If this is the case, the view that institutionalisation is 
associated with large increases in costs could be challenged. 
To address this knowledge gap, it is important to have a 
complete set of input data for modelling the whole course 
of AD. There is also a need for better understanding of the 
factors that influence institutionalisation and of interventions 
that enable persons with AD dementia to remain in the com-
munity for longer.
Prospective observational studies such as the GERAS 
study, of the costs and resource use associated with commu-
nity-dwelling patients with AD dementia and their caregivers 
[12], may provide useful long-term data on the time to insti-
tutionalisation in usual clinical practice as well as predictive 
factors and the relationship between time to institutionalisa-
tion and costs.
The aims of the current study were to estimate the health-
care and societal costs of caring for community-dwelling 
patients with AD dementia in relation to the time to insti-
tutionalisation. We present a proof-of-concept methodo-
logical approach for modelling disease progression and 
costs in patients with AD dementia for use in a cost-effec-
tiveness model, using the GERAS population as an exam-
ple. By applying the results of the GERAS study, we first 
assessed the cumulative incidence of institutionalisation 
over 36 months of follow up and identified factors asso-
ciated with time to institutionalisation. Using these fac-
tors, we developed parametric models to estimate time to 
institutionalisation for all patients and then estimated health-
care and societal costs as a function of time to institutionali-
sation from the parametric models.
Methods
GERAS study design
GERAS was an 18-month prospective observational study 
of costs associated with the care of community-dwelling 
patients with AD dementia and their caregivers in three 
European countries (France, Germany, UK) [12]. The study 
design, patient characteristics and baseline costs have been 
reported in detail elsewhere [12].
The study enrolled community-dwelling patients aged 
at least 55 years, meeting the National Institute of Neuro-
logical and Communicative Disorders and Stroke/Alzhei-
mer’s Disease and Related Disorders Association criteria 
for probable AD [13], with a Mini-Mental State Examina-
tion (MMSE) [14] score of ≤ 26, and presenting within the 
normal course of care. Patients were stratified by disease 
severity at baseline, as reported previously [12]: mild AD 
dementia (MMSE score = 21‒26), moderate AD demen-
tia (MMSE score = 15‒20), moderately severe/severe 
(MS/S) AD dementia (MMSE score < 15). Ethical review 
board approval of the study was obtained in each country 
in accordance with individual country regulations. Written 
informed consent was obtained from all participants or their 
legal representative.
Data collection
Data were collected at baseline and during routine care visits 
at 6, 12 and 18 months in all three countries and at 24, 30 
and 36 months in France and Germany. Information col-
lected for patients and caregivers included sociodemograph-
ics, comorbidities, medications, and health-related quality 
of life (HRQoL).
Patient cognitive function was assessed using the MMSE, 
with lower scores indicating reduced cognitive functioning. 
Functional ability was assessed using the Alzheimer’s Dis-
ease Cooperative Study Activities of Daily Living inventory 
(ADCS-ADL) [12, 15, 16], which was completed on behalf 
of the patient by his/her caregiver. The range for the total 
ADCS-ADL score is 0–78. Separate subscores were derived 
for basic activities of daily living (ADL; basic ADCS-ADL 
score range 0–22) and instrumental ADL (instrumental 
ADCS-ADL score range 0–56), with higher scores indicat-
ing better functioning for the total score and subscores [12]. 
Behavioural and psychological symptoms were assessed by 
the patient’s caregiver using the Neuropsychiatric Inventory 
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(NPI)-12 [17] where a higher NPI-12 total score indicates 
more severe problems.
Information on healthcare resource use by patients and 
caregivers was collected using the Resource Utilization in 
Dementia (RUD) instrument [18] and several additional 
questions during interview. Resource use items collected 
included healthcare (medications, outpatient visits, hospital 
stays, emergency room visits, neuropsychological assess-
ments), social care (community care services, such as dis-
trict nurse, home aid, food delivery, day care, transportation, 
other; financial support, out-of-pocket expenses), changes to 
patient living accommodation (permanent, temporary; struc-
tural adaptations; institutionalisation), caregiver work status 
(working for pay [yes/no], lost work time) and caregiver time 
(i.e. time spent on giving informal care by the primary car-
egiver). Caregiver informal care time was recorded as time 
spent assisting the patient with basic ADL (e.g. bathing, 
feeding) and instrumental ADL (e.g. shopping, cooking), 
and was capped at 24 h/day. Details of other data collected 
but not used in the present analyses are available elsewhere 
[12].
Cost estimation
Monthly costs values were estimated by applying country-
specific unit costs of services and products (2010 values) to 
the healthcare and social care resource use data collected 
over the 36-month follow-up period. Full details of the 
unit costs applied and their sources are presented in Online 
Resource 1.
Total societal costs were evaluated using an opportu-
nity cost approach taking into account productivity loss for 
working caregivers and lost leisure time for non-working 
caregivers. Costs were calculated for the month before each 
visit. Total societal costs were calculated by combining 
direct costs, consisting of patient healthcare costs (includ-
ing medications, hospitalisations and outpatient visits) and 
patient social care costs (including community care services, 
structural adaptations, financial support and out-of-pocket 
expenses), and indirect costs, consisting of caregiver infor-
mal care costs (including the time spent giving care and 
missing work). Total patient costs were analysed as patient 
healthcare costs and patient social care costs combined. 
The list of resource use items collected in the section above 
reflects all cost categories included in the cost analyses.
The following imputation rules were applied for miss-
ing data: for institutionalised patients, mean monthly costs 
from the last visit were used for the period until institu-
tionalisation and monthly costs for institutionalisation were 
used from institutionalisation up to 18 months for the UK 
and up to 36 months for France and Germany. For patients 
who died, last observation carried forward was used such 
that costs from the last known visit were extrapolated up to 
the date of death (no costs after death were computed). For 
patients with other reasons for discontinuation, the multi-
ple imputation regression method [19] stratified by MMSE 
group and country was applied to missing costs. The list 
of factors used in the multiple imputation procedure was 
selected from those identified by Dodel et al. [20]. Fixed 
costs were applied to institutionalised patients (see Online 
Resource 1) and zero costs were applied once a patient died. 
Thus, multiple imputation was only used for patients with 
other reasons for discontinuation, including lost to follow up.
The unit cost of caregiver time for working caregivers 
was the value of lost production time based on the national 
average wage per country; for non-working caregivers, it was 
the value of lost leisure time based on 35% of the national 
average wage per country population (see Wimo et al. [12]). 
In the current analyses, French and German costs were con-
verted from euros to pounds sterling using the conversion 
rate €1 = £0.8576 (calculated using the monthly exchange 
rate average for 2010 as reported previously [12]). The cost 
data are presented in pounds sterling because one aim of 
the study was to develop economic models for the National 
Institute for Health and Care Excellence (NICE) in the UK. 
However, overall monthly cost estimates are also given in 
euros (calculated using the conversion rate above).
Time to institutionalisation
Time to institutionalisation was taken from the reasons for 
discontinuation from the study, where the date of institution-
alisation was collected if the reason for discontinuation was 
reported as patient institutionalisation. The current analysis 
did not include temporary admission to an institution or full-
time care at home based on caregiver time or responses to 
specific basic ADL questions. Time to institutionalisation 
was measured in days from the date of the baseline assess-
ment to the date of institutionalisation.
Statistical analyses
Demographics and baseline characteristics were summarised 
using descriptive statistics and were based on non-missing 
observations.
Competing risk analysis [21], where institutionalisation 
and death were considered as competing risks, was used 
to describe the cumulative incidence of institutionalisation 
during the 36-month follow-up period for the total study 
population.
Factors associated with time to institutionalisation 
were explored using Cox proportional hazards models of 
the 36-month data (18 months for the UK data); time to 
institutionalisation was censored at the time of last follow 
up or time to death for those subjects who did not report 
being institutionalised. The only competing risk in the Cox 
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proportional hazards models was patient death, which was 
treated as a censored event (i.e. the patient was considered 
to have died before institutionalisation). One hundred dif-
ferent models using forward and backward selection were 
run, selecting 67% of subjects at random for inclusion in the 
model, and the factors identified in each model summarised. 
Entry and exclusion of individual factors was based on a 
significance level of 0.05. Patient characteristics considered 
in the models were age, gender, years of education, time 
since diagnosis of AD, comorbidities, and baseline scores 
for MMSE, total ADCS-ADL, instrumental ADCS-ADL, 
basic ADCS-ADL and NPI-12 total. Caregiver characteris-
tics considered in the models were age, gender, relationship 
with patient (spouse yes/no), and caregiver working for pay 
(yes/no).
Additional analyses examined the effects of including AD 
medication as a factor in the model selection, or including 
the four subdomains of ADCS-ADL (basic activities, house-
hold activities, communication, outdoor activities) or four 
subdomains of NPI (psychosis, affective, apathy, hyperac-
tivity) in the list of variables for consideration in the mod-
els, as well as interactions between the scores for cognition 
(MMSE) and function (ADCS-ADL). If the final selection 
suggested a subdomain rather than a main effect, then the 
models were compared based on their Akaike Information 
Criterion (AIC) and Bayesian Information Criterion (BIC) 
model fit statistics. If the difference was less than 3 then 
the model with total score rather than subdomain was used.
Any factor found to be significant in over 75% of the 
models was included in the parametric models used to pre-
dict time to institutionalisation. Again, the only competing 
risk in the parametric models was patient death, which was 
treated as a censored event in the analysis. To allow for dif-
ferent assumptions around the distribution of the data, the 
parametric models considered exponential, log-logistic, 
Weibull, log-normal and gamma distributions. Model fit 
was assessed using AIC and BIC model fit statistics, and 
the best fitting model was selected for use in the model that 
estimated societal and patient costs as a function of time to 
institutionalisation.
Models were fitted to estimate costs (y) as a func-
tion of time to institutionalisation (x). Separate models 
were developed for total societal costs, total patient costs 
(patient healthcare plus social care costs) and patient health-
care costs, determined using the cost category definitions 
described earlier. These three cost categories were chosen 
as they were considered to be the most important for payers. 
For each patient, the predicted time to institutionalisation 
(Pred_Inst) was calculated from the parametric model. Then, 
for each 6-month visit, the patient’s time to institutionalisa-
tion (Pre-Inst) was calculated as: Pre-Inst = Pred_Inst-visit. 
Each individual subject time point was treated as independ-
ent, had an associated cost and any missing cost visits used 
the imputation methods described earlier. The cost analysis 
only used data for the first 18 months so that data from all 
three countries could be used.
All data were analysed using SAS version 9.2 (SAS Insti-
tute, Cary, NC, USA).
Results
The GERAS study included 1495 patients at baseline: 566 
(37.9%) patients had mild AD dementia, 472 (31.6%) had 
moderate AD dementia and 457 (30.6%) had MS/S AD 
dementia. Table 1 presents the patient and caregiver char-
acteristics at baseline for the overall cohort and by mild, 
moderate and MS/S AD dementia severity.
Of the 1495 patients at baseline, 307 (20.5%) were insti-
tutionalised during the 36-month follow-up period: 122/419 
(29.1%) patients from France, 91/550 (16.5%) patients 
from Germany, and 94/526 (17.9%) patients from the UK 
(18 months’ follow up for the UK). According to baseline 
AD dementia severity, the number (%) of patients institu-
tionalised during follow up was 66 (11.7%), 111 (23.5%) and 
130 (28.4%) in the mild AD, moderate AD and MS/S AD 
dementia groups, respectively. An additional 152 (10.2%) 
patients died overall before institutionalisation during the 
36-month follow-up period. Other reasons for discontinu-
ation included lost to follow up [57 (3.8%) patients], phy-
sician decision [32 (2.1%) patients], sponsor decision [1 
(0.07%) patient], subject decision [206 (13.8%) patients] 
and subject entered clinical trial [2 (0.1%) patients].
Of the 1495 patients, only 11 were excluded from the time 
to institutionalisation analysis due to missing data. Figure 1 
presents the cumulative incidence of institutionalisation over 
36 months by AD dementia severity at baseline from the 
competing risk analysis. It shows that patients with greater 
disease severity at baseline have a higher risk of being insti-
tutionalised at 36 months; the Wald test for comparison 
across groups with mild, moderate and MS/S AD dementia 
was significant (p < 0.001).
Table 2 summarises the maximum likelihood parameter 
estimates of factors independently associated with time to 
institutionalisation from the 36-month data. Interpretation 
of regression coefficients shows that having a non-spousal 
caregiver was associated with a faster time to institution-
alisation (944 fewer days to institutionalisation versus hav-
ing a spousal caregiver), as was a worse baseline score 
in MMSE, instrumental ADCS-ADL and NPI-12 (67, 50 
and 30 fewer days, respectively, for each one-point wors-
ening in baseline score). However, a worse basic ADCS-
ADL score at baseline was associated with a longer time 
to institutionalisation (89 days for each one-point change 
in score). Therefore, the following patient and caregiver 
factors were selected for inclusion in the final model to 
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determine time to institutionalisation: MMSE total score at 
baseline, basic ADCS-ADL score at baseline, instrumental 
ADCS-ADL score at baseline, NPI-12 total score at base-
line and caregiver relationship (spouse yes/no).
Additional analyses (data not shown) demonstrated 
that when AD medication was included as a factor, it did 
not enter into the final model. When the model selection 
included the baseline scores for the four ADCS-ADL sub-
domains (basic activities, household activities, communi-
cation, outdoor activities), the communication subdomain 
was selected and had lower AIC values than instrumental 
ADCS-ADL but the difference was not significant. When 
the NPI subdomains were included in the model, the NPI-
12 total score was more predictive than if it were replaced 
with a specific subdomain.
Figure 2 presents the time to institutionalisation extrapo-
lated beyond 36 months to 9125 days (25 years; beyond the 
expected lifetime of the patients) for the different model 
distributions examined in models of the 36-month data 
that included patient and caregiver factors as described in 
Table 2. It shows that differences exist when extrapolating 
beyond the 36-month study period and highlights the impact 
associated with the choice of model. The models used sug-
gest that, even after 10 years, not all patients would have 
been institutionalised. Model fits (based on AIC and BIC) 
were similar for the different distributions within the study 
period.
From the time-to-institutionalisation models, we chose 
the log-normal distribution to model the relationship 
between costs and time to institutionalisation as it had the 
Table 1  Baseline characteristics of patients and caregivers in the overall study population and by AD dementia severity
All data are based on patients/caregivers with non-missing data (baseline characteristics data missing for two caregivers)
AD Alzheimer’s disease, ADCS-ADL Alzheimer’s Disease Cooperative Study Activities of Daily Living inventory, MMSE Mini-Mental State 
Examination, MS/S moderately severe/severe, N/A not applicable, NPI neuropsychiatric inventory, SD standard deviation
a p value for comparison between AD dementia severity groups (ANOVA for continuous variables, Cochran–Mantel–Haenszel for categorical 
variables)
b MMSE total score range 0‒26; enrolled patients were stratified according to baseline disease severity as having mild (MMSE 21–26 points), 
moderate (MMSE 15–20 points) or moderately severe/severe AD dementia (MMSE < 15 points)
c ADCS-ADL total score range 0‒78
d Basic ADCS-ADL score range 0‒22
e Instrumental ADCS-ADL score range 0‒56
f NPI-12 total score range 0‒144
Characteristics Overall Mild AD Moderate AD MS/S AD p  valuea
Patient, n 1495 566 472 457
 Gender, n (%) female 819 (54.8) 271 (47.9) 269 (57.0) 279 (61.1) < 0.001
 Age, mean (SD) 77.6 (7.7) 77.3 (6.9) 77.8 (8.0) 77.6 (8.1) 0.934
 Education, years, mean (SD) 10.4 (3.2) 11.1 (3.3) 10.1 (2.9) 10.0 (3.0) < 0.001
 Time since diagnosis of AD, years, mean (SD) 2.2 (2.2) 1.7 (2.0) 2.1 (2.0) 3.1 (2.4) < 0.001
 Patients with comorbidities, n (%) 1101 (73.6) 426 (75.3) 345 (73.1) 330 (72.2) 0.340
 Number of comorbidities per patient, mean (SD) 1.4 (1.2) 1.5 (1.2) 1.4 (1.2) 1.4 (1.3) 0.608
 MMSE total  scoreb, mean (SD) 17.4 (6.3) 23.3 (1.6) 17.9 (1.7) 9.5 (4.3) N/A
 ADCS-ADL total  scorec, mean (SD) 46.5 (19.5) 58.4 (14.2) 48.3 (15.4) 29.9 (17.2) < 0.001
 Basic ADCS-ADL  scored, mean (SD) 17.3 (5.2) 19.8 (3.1) 18.3 (3.8) 13.2 (6.0) < 0.001
 Instrumental ADCS-ADL  scoree, mean (SD) 29.1 (15.2) 38.5 (11.8) 29.9 (12.5) 16.6 (12.3) < 0.001
 NPI-12 total  scoref, mean (SD) 15.1 (15.3) 10.2 (10.7) 14.3 (12.6) 22.0 (19.4) < 0.001
Caregiver, n 1493 565 472 456
 Gender, n (%) female 958 (64.2) 387 (68.5) 305 (64.6) 266 (58.3) 0.004
 Age, mean (SD) 67.3 (12.0) 68.1 (11.6) 66.7 (11.7) 67.0 (12.9) 0.084
 Relationship to patient, n (%) 0.024
  Spouse 984 (65.9) 399 (70.6) 298 (63.1) 287 (62.9)
  Child 405 (27.1) 133 (23.5) 136 (28.8) 136 (29.8)
  Other 104 (7.0) 33 (5.8) 38 (8.1) 33 (7.2)
 Lives with patient, n (%) 1135 (76.0) 429 (75.9) 341 (72.2) 365 (80.0) 0.018
 Working for pay, n (%) 355 (23.8) 133 (23.5) 120 (25.4) 102 (22.4) 0.457
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best fit of the available data (lowest AIC and BIC values). 
Table 3 summarises the regression estimates from the log-
normal models estimating costs (total societal costs, total 
patient costs, patient healthcare costs) as a function of time 
to institutionalisation. Country-specific regression estimates 
are presented in Online Resources 2–4. Overall, costs were 
imputed by multiple imputation for 298 (19.9%) patients: 
118 (20.8%) in the mild AD dementia group, 85 (18.0%) 
in the moderate AD dementia group and 95 (20.8%) in the 
MS/S AD dementia group. Monthly total societal costs and 
total patient costs were associated with time to institution-
alisation; these costs increased substantially in the 5 years 
prior to institutionalisation (Fig. 3). In the 5 years before 
institutionalisation, estimated monthly total societal costs 
increased by more than £1000 (€1166) from £1900 (€2216) 
to £3160 (€3685) and estimated monthly total patient costs 
almost doubled from £770 (€898) to £1529 (€1783) (see 
Fig. 3). Patient healthcare costs were associated with time to 
institutionalisation (Table 3) but increased relatively moder-
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Fig. 1  Cumulative incidence of institutionalisation over 36 months by 
AD dementia severity at baseline. *p < 0.001 for comparison across 
groups with mild, moderate and MS/S AD dementia (Wald test). AD 
Alzheimer’s disease, CL confidence limits, MS/S moderately severe/
severe
Table 2  Analysis of maximum likelihood parameter estimates of patient and caregiver factors associated with time to institutionalisation from 
the log-normal model of the 36-month data
ADCS-ADL Alzheimer’s Disease Cooperative Study Activities of Daily Living inventory, MMSE Mini-Mental State Examination, NPI Neu-
ropsychiatric Inventory
a The regression coefficient gives the change in time based on a one-point increase in the factor (for continuous factors) or the difference in time 
(for categorical factors) from the reference value. A one-point increase in score for MMSE and ADCS-ADL represents an improvement, while a 
one-point increase in NPI-12 score represents a worsening
b The method of calculating change in time to institutionalisation is available upon request. A negative sign indicates fewer days to institutionali-
sation. The interpretation is that a one-point worsening in MMSE score (i.e. a lower score) results in 67 fewer days (2.3 months) to institutionali-
sation; a one-point worsening in instrumental ADCS-ADL score (i.e. a lower score) results in 50 fewer days (1.7 months) to institutionalisation; 
a one-point worsening in basic ADCS-ADL score (i.e. a lower score) results in 89 more days (3.0 months) to institutionalisation; a one-point 
worsening in NPI-12 total score (i.e. a higher score) results in 30 fewer days (1.0 month) to institutionalisation; and patients with a non-spousal 
caregiver have 944 fewer days (31.5 months) to institutionalisation than those with spousal caregivers
c Score at baseline
d See “Discussion” for possible explanations for this finding
Variables Regression 
 coefficienta
Standard error 95% confidence limits χ2 p value Change in time to 
institutionalisation, days 
(months)b
Intercept 7.600 0.209 7.190; 8.010 1321.79 < 0.0001 –
MMSE total  scorec 0.034 0.009 0.016; 0.052 13.75 0.0002 − 67 (2.3)
Instrumental ADCS-ADLc 0.025 0.005 0.015; 0.036 23.44 < 0.0001 − 50 (1.7)
Basic ADCS-ADLc − 0.044 0.014 − 0.071; − 0.017 10.13 0.0015 + 89 (3.0)d
NPI-12 total  scorec − 0.015 0.003 − 0.021; − 0.010 27.35 < 0.0001 − 30 (1.0)
Spousal caregiver, No (Ref = yes) − 0.640 0.095 − 0.826; − 0.453 45.18 < 0.0001 − 944 (31.5)
Scale 1.206 0.054 1.105; 1.317 – – –
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Discussion
Our results in community-dwelling patients with AD demen-
tia from the GERAS study showed that, during the 5 years 
prior to institutionalisation, estimated monthly total societal 
costs increased steeply and total patient costs almost dou-
bled, without a substantial rise in patient healthcare costs 
(i.e. direct medical costs including hospitalisations, visits to 
general practitioners and specialists, and medication). These 
findings reflect escalating caregiver informal care costs and 
patient social care costs as a patient approaches institutional-
isation, which are probably due to increasing patient depend-
ence resulting from worsening disease severity.
The difference between total societal costs and total 
patient costs is likely a result of caregiver informal care 
costs, which are the main component of societal costs [12] 
and remain so irrespective of differences in the unit costs 
used to calculate the different components of informal care 
costs, such as country-specific wages [12, 20, 22]. Infor-
mal care is largely driven by the functional ability of the 
patient, and greater impairment in ADL is an important 
predictor of societal costs [23, 24]. Our finding that total 
societal costs rise steeply as community-living patients 
approach institutionalisation suggests that institutionalisa-
tion per se may not result in a huge increase in societal costs 
when caregiver informal care costs are included. However, 
institutionalisation results in a shift from unpaid informal 
care to a direct cost for the provider of institutional care, 
and there are few data available on resource use and costs by 
category following institutionalisation [2]. Our findings are 
consistent with a recent cross-sectional study in Germany, 
which showed that the societal costs of care for dementia 
patients living in the community were higher than those for 
institutionalised patients after controlling for various fac-
tors including functional impairment and when including 
a value for informal care [25]. However, a study in eight 
European countries of the costs of caring for people with 
dementia showed that monthly societal costs for recently 
institutionalised patients were almost twofold higher than 
those for patients receiving home care [5]. Although the 
authors speculated that delaying institutionalisation may 
be cost-saving from a societal perspective, they pointed out 
that this depends on the country, the value given to infor-
mal caregiver time and the level of patient impairment [5]. 
Patients with a very low level of ADL independence in the 
community-care setting might have higher costs compared 
to those in the institutional care setting; thus, delaying insti-
tutionalisation for such patients would not be cost-reducing. 
Using baseline data from the GERAS study, Reed et al. [26] 
showed that higher total societal costs were associated with 
impairment in all aspects of ADL and that patient healthcare 
and social care costs were associated with total ADL and 
basic ADL but not instrumental ADL.
A recent insurance claims data analysis of patients with 
dementia in Germany showed that healthcare service utili-
sation (e.g. physician visits, inpatient days, drug prescrip-
tions) and related costs increased in the 3 months leading up 
to institutionalisation and then stabilised or decreased [27]. 
That study took a payer’s perspective and did not include a 
value for informal care in the community setting. Moreover, 
the authors stated that institutional care might be the less 
costly option from a societal perspective. In our study, patient 
healthcare costs represented only a small proportion of the 
total societal costs [12] and increased only moderately during 
the 5 years before institutionalisation. The difference between 
our study and the German insurance claims study in the pat-
tern of healthcare costs prior to institutionalisation could have 
been due to specific characteristics of the GERAS popula-
tion, a greater likelihood that GERAS study participants were 
already relatively high-cost patients when they entered the 
study (patients were required to have an informal caregiver 
to enter GERAS, which would incur associated costs [12, 
20, 22]), differences between countries in care provision, or 
that the increasing care needs of the patients were being met 
by caregivers or social care. Patient healthcare costs are not 
dependent on patient AD severity; in each of the countries 
participating in the GERAS study, patient healthcare costs 
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Fig. 2  Extrapolation plots of time to institutionalisation beyond 
36 months for the different model distributions examined in models 
of the 36-month data that included patient and caregiver factors. Data 
cut-off = 9125  days (25  years). AIC Akaike Information Criterion, 
BIC Bayesian Information Criterion
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Factors associated with institutionalisation
The regression model found that having a non-spousal car-
egiver, poorer cognition (MMSE), greater functional impair-
ment in instrumental ADL and worse behavioural distur-
bance (NPI-12) were all independently associated with a 
faster time to institutionalisation over 36 months.
Yaffe et al. [4] showed that multivariate models which 
combine patient and caregiver factors are better able to 
predict time to institutionalisation than a model including 
patient factors alone. In our analysis, caregiver relationship 
had the greatest impact on time to institutionalisation. Our 
results showing that having a non-spousal caregiver was 
associated with a faster time to institutionalisation (over 
2.5 years compared with having a spousal caregiver) are in 
line with those of Hébert et al. [28] who reported that having 
a spouse as a caregiver was a protective factor. Additionally, 
in their systematic review, Luppa et al. [3] showed earlier 
institutionalisation among patients when their caregiver is 
a child or other relative rather than a spouse. Moreover, in 
their study of community-dwelling patients with AD, Soto 
et al. [29] found that living alone or with family presented a 
higher risk of institutionalisation than living with a spouse. 
Table 3  Estimates from the log-
normal regression models of the 
association between costs and 
time to institutionalisation
Time to institutionalisation (Pre-Inst in equations below) is in years
Estimates can be converted into the following equations:
EQ1: Total societal costs (£) = 3159.68 − (334.03 Pre-Inst) + (18.57 Pre-Inst2) − (0.43 Pre-Inst3)
EQ2: Total patient costs (£) = 1528.96 − (208.53 Pre-Inst) + (12.73 Pre-Inst2) − (0.28 Pre-Inst3)
EQ3: Patient healthcare costs (£) = 348.31 − (14.88 Pre-Inst) + (0.35 Pre-Inst2)
For example, using EQ1 and Pre-Inst = 3 to estimate monthly total societal costs at 3 years prior to institu-
tionalisation:
Total societal costs (£) = 3159.68 − (334.03 × 3) + (18.57 × 32) − (0.43 × 33)
Total societal costs (£) = 3159.68 − (1002.09) + (167.13) − (11.61)
Total societal costs (£) = 2313.11
a The superscripts 2 and 3 refer to the quadratic and cubic terms, respectively, of the variable ‘time to insti-
tutionalisation’
Estimate Standard error tValue p value
Total societal  costsa
 Intercept 3159.677 85.466 36.97 < 0.0001
 Time to institutionalisation − 334.025 38.541 − 8.67 < 0.0001
 Time to  institutionalisation2 18.572 4.851 3.83 0.0001
 Time to  institutionalisation3 − 0.434 0.174 − 2.49 0.0128
Total patient  costsa
 Intercept 1528.964 54.984 27.81 < 0.0001
 Time to institutionalisation − 208.529 24.522 − 8.50 < 0.0001
 Time to  institutionalisation2 12.733 3.062 4.16 < 0.0001
 Time to  institutionalisation3 − 0.284 0.109 − 2.59 0.0095
Patient healthcare  costsa
 Intercept 348.306 22.813 15.27 < 0.0001
 Time to institutionalisation − 14.883 6.223 − 2.39 0.0168
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Fig. 3  Estimated monthly total societal costs, total patient costs and 
patient healthcare costs by time to institutionalisation (years)
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Further studies have found that patients who live alone have 
an increased risk of institutionalisation compared with those 
who live with others [3, 30, 31]. Additional caregiver fac-
tors that may affect time to institutionalisation of patients 
with AD dementia include caregiver age, health, depres-
sion and burden [3, 4, 28, 31]. Studies have shown earlier 
institutionalisation among patients when their caregivers are 
employed, have a higher level of education or have a higher 
income [3]. Caregiver factors associated with institution-
alisation of people with AD in the LASER-AD study were 
having a paid versus family carer, and the carer being less 
educated and spending fewer hours caring [32].
Our finding that several patient factors are associated with 
time to institutionalisation is in accordance with previous 
research. There is now considerable evidence that poorer 
cognition and lower functional abilities at baseline are 
associated with earlier institutionalisation of patients with 
dementia [3, 32‒35]. Most studies assessed overall func-
tional ability (i.e. basic and instrumental ADL), although 
some assessed instrumental ADL separately [33, 35]. A 
deterioration in instrumental ADL is usually observed in 
patients with AD before a decline in basic ADL [36]. In a 
modelling analysis of data from a randomised controlled 
trial of AD patients receiving rivastigmine or donepezil 
treatment for up to 2 years, Hatoum et al. [37] showed that 
lower baseline ADL scores (total, basic and instrumental 
ADL) were all independently associated with a faster time 
to institutionalisation. In our analysis, both basic and instru-
mental ADL scores were included in the multivariate model. 
It is unclear why a worse baseline basic ADCS-ADL score 
was associated with a longer time to institutionalisation in 
our study, whereas a worse baseline instrumental ADCS-
ADL score was associated with a faster time to institution-
alisation, but there may be several reasons. First, because 
there is a high correlation between cognition and function, 
when both factors are included in the same model, one of 
the variables moves in the opposite direction compared with 
when it is fitted independently [24]. Thus, the inclusion of 
baseline MMSE score in our model may have influenced the 
association between baseline basic ADCS-ADL score and 
time to institutionalisation. Another possible explanation for 
our finding that a worse baseline basic ADCS-ADL score 
was associated with a longer time to institutionalisation may 
be that the patients were already incapacitated and highly 
dependent on their caregiver, but were well supported and 
receiving more community-based services.
Our result showing that worse patient behavioural prob-
lems at baseline were associated with a faster time to institu-
tionalisation is also consistent with some previous research 
[30, 34, 38, 39]. Although some analyses found that differ-
ent NPI domains or individual neuropsychiatric symptoms 
were more relevant [34, 39], the NPI-12 total score was the 
most important in our analysis. Other studies have found that 
patient sociodemographics are associated with institution-
alisation: patients who are older or male have an increased 
risk of and/or shorter time to institutionalisation, whereas 
those with a higher level of education have a longer time to 
institutionalisation [3].
In a 3-year prospective naturalistic study in Sweden, 
multivariate analyses showed that worse baseline MMSE 
and instrumental ADL scores were associated with a faster 
time to institutionalisation, as were the patient living alone, 
a lower versus higher dose of acetylcholinesterase inhibitor, 
an increase of more than 7 h per week of home help services 
and an increase of more than 3 days per week of adult day 
care [35]. When AD treatment was included in our addi-
tional analysis of further potential factors in the model selec-
tion, it did not enter the final model, meaning that use of ace-
tylcholinesterase inhibitors or memantine was not shown to 
be associated with time to institutionalisation. Randomised 
controlled trials have provided conflicting results regarding 
delaying institutionalisation with acetylcholinesterase inhibi-
tors and/or memantine in community-living patients with 
AD [40, 41]. Also, in an observational study in the USA, 
Lopez et al. [42] found that treatment with an acetylcho-
linesterase inhibitor alone or in combination with memantine 
prolonged the time to institutionalisation of patients with AD 
compared with untreated patients. The data from the Lopez 
study have been applied to economic models in several coun-
tries and have shown that combination therapy is cost-saving 
from a societal perspective [43, 44].
Importantly, we observed differences in the time to insti-
tutionalisation when extrapolating beyond the 36-month 
study period using models with different distributions (see 
Fig. 2). This demonstrates uncertainty around long-term out-
comes and indicates the need for more long-term follow-up 
data [45] and sensitivity analyses, as recommended by NICE 
[46]. Our results highlight the importance of choosing the 
correct extrapolation model, since the use of different mod-
els can produce very different results [46].
This methodology could be applied to country-specific 
cost-effectiveness models through the use of country-spe-
cific data sources (as shown in Online Resources 2–4).
Strengths and limitations
The study has a number of strengths. It consisted of a large, 
community-based sample of patients with AD, and included 
patients across a wide range of AD severity, assessed using 
standardised instruments and followed for up to 3 years. We 
also used a transparent methodology for our cost estima-
tions. Only 11 patients were excluded from the time to insti-
tutionalisation analysis due to missing data. The numbers of 
missing patients in the cost analyses were not related to the 
severity of disease, as the proportion of missing patients was 
similar in each disease severity group.
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However, there are some limitations. First, in the mod-
els used, we assumed a log-normal distribution when 
extracting beyond the 36-month observational period. 
However, as can be seen in Fig. 2, the choice of distri-
bution will affect the slope of these curves. Other distri-
butions should be included in sensitivity analyses when 
using this methodology for cost-effectiveness modelling. 
In addition, sensitivity analyses involving other types of 
costing methods, such as replacement costs, should be per-
formed. Longer term follow-up data on time to institution-
alisation, which are continuing to be collected, will reduce 
the uncertainty introduced when extrapolating beyond the 
study period. Also, the parametric survival model may not 
fit the data perfectly. Second, patient age was not included 
in our final model because it was a non-significant covari-
ate, but it has been associated with a faster time to insti-
tutionalisation in other studies [3]. Patient age may have 
been excluded from the final model due to inclusion of the 
caregiver relationship, i.e. older patients are more likely 
to have a non-spousal caregiver [47]. Also, we did not 
control for the progression of dementia, which could be 
achieved by calculating a measure that displays differ-
ences in cognitive functioning or status of independence. 
It is feasible that costs could be driven by fast progress-
ing dementia while other non-problematic trajectories 
remain undiscovered. Third, we analysed combined data 
from three high-income European countries, but time to 
institutionalisation for patients in each country will be 
influenced by the availability of long-term care institutions 
and resources, and national policies on the organisation 
of dementia care [8, 48‒50]. In low- and middle-income 
countries, where resources are scarce, institutionalisation 
rates are consequently low [50]. There are also cultural dif-
ferences between and within countries in the preferences 
for institutional care, which limits the generalisability of 
our findings. Moreover, institutionalisation may occur for 
many reasons, which may vary between countries [51], 
and for reasons that may be unrelated to AD. Fourth, the 
risk of, or time to, institutionalisation may be affected by 
non-pharmacological interventions or other variables not 
collected as part of the GERAS study [52], but informa-
tion on any such interventions in patients and/or caregivers 
was not collected. The risk of institutionalisation will also 
change over time, as shown by Howard et al. [41]. The 
variables associated with institutionalisation will also vary 
with time, but we only included baseline variables in our 
analyses. Long-term data from the GERAS study could be 
used to explore the risks of institutionalisation and effects 
on costs. Fifth, there is possible selection bias due to the 
recruitment of the study participants mostly from memory 
clinics, which may limit the generalisability of the find-
ings as the sample is not fully representative of all AD 
patients living in the community. Furthermore, the role of 
family caregivers does not finish upon institutionalisation 
of their relative; they may continue to experience stress 
and financial pressures after the transition to institutional 
care [53]; this should be considered when taking a soci-
etal approach to costs. As we did not estimate costs after 
institutionalisation, we could not compare costs before and 
after institutionalisation.
Conclusions
This proof-of-concept model demonstrates that total soci-
etal costs and total patient costs rise steeply as community-
dwelling patients with AD dementia approach institution-
alisation, whereas patient healthcare costs increase only 
moderately. The main cost impact is from caregivers and 
community services, which varies according to patient 
functional ability and dependence. Caregiver factors are 
important in understanding the risk of institutionalisation 
in community-living patients with AD dementia. The key 
caregiver factor in this community-based cohort is being a 
non-spouse of the patient, which was associated with a faster 
time to institutionalisation (over 2.5 years). The implications 
of this finding are that we may need to invest in better com-
munity support for caregivers who want to keep patients 
with AD at home, although this will be more costly from a 
societal perspective. There is a need for long-term data to 
fully understand the patterns and costs of institutionalisation.
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